» Articles » PMID: 26758515

Parathyroidectomy Associates with Reduced Mortality in Taiwanese Dialysis Patients with Hyperparathyroidism: Evidence for the Controversy of Current Guidelines

Overview
Journal Sci Rep
Specialty Science
Date 2016 Jan 14
PMID 26758515
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Parathyroidectomy is recommended by the clinical guidelines for dialysis patients with unremitting secondary hyperparathyroidism (SHPT). However, the survival advantage of parathyroidectomy is debated because of the selection bias in previous studies. To minimize potential bias in the present nationwide cohort study, we enrolled only dialysis patients who had undergone radionuclide parathyroid scanning to ensure all patients had severe SHPT. The parathyroidectomized patients were matched with the controls based on propensity score for parathyroidectomy. Mortality hazard was estimated using multivariate Cox proportional hazard models adjusting for comorbidities before scanning (model 1) or over the whole study period (model 2). Our results showed that among the 2786 enrolled patients, 1707 underwent parathyroidectomy, and the other 1079 were controls. The crude mortality rates were lower in the parathyroidectomized patients than in the controls. In adjusted analyses for the population matched on propensity score, parathyroidectomy was associated with a significant 20% to 25% lower risk for all-cause mortality (model 1: hazard ratio 0.76, 95% confidence interval 0.61 to 0.94; model 2: hazard ratio 0.80, 95% confidence internal 0.64 to 0.98). We concluded that parathyroidectomy was associated with a reduced long-term mortality risk in dialysis patients with severe SHPT.

Citing Articles

Effect of sodium zirconium cyclosilicate on hyperkalemia after parathyroidectomy in secondary hyperparathyroidism patients with maintenance hemodialysis: A randomized trial.

Kang J, Li S, Su J, Xiao Z, Zhang S, Liu S Medicine (Baltimore). 2025; 103(52):e40917.

PMID: 39969301 PMC: 11688067. DOI: 10.1097/MD.0000000000040917.


Parathyroid hormone-PTH1R signaling in cardiovascular disease and homeostasis.

Towler D Trends Endocrinol Metab. 2024; 35(7):648-660.

PMID: 38429163 PMC: 11233248. DOI: 10.1016/j.tem.2024.02.005.


Total parathyroidectomy with forearm autotransplantation in secondary hyperparathyroidism patients: analysis of muscle, subcutaneous and muscle + subcutaneous method.

Zhou B, Zhu L, Xiang C, Cheng F, Zhu X, Zhou Y BMC Surg. 2021; 21(1):226.

PMID: 33933053 PMC: 8088620. DOI: 10.1186/s12893-021-01222-2.


Impact of parathyroidectomy on left ventricular function in end stage renal disease patients.

Chen S, Sheng K, Shen Y, Jiang H, Lei X, Qu L BMC Nephrol. 2020; 21(1):479.

PMID: 33187492 PMC: 7666516. DOI: 10.1186/s12882-020-02139-3.


Risk factors predicting severe hypocalcemia after total parathyroidectomy without autotransplantation in patients with secondary hyperparathyroidism.

Liu J, Huang Q, Yang M, Huang L, Zhang L J Int Med Res. 2020; 48(1):300060519897505.

PMID: 31948313 PMC: 7113811. DOI: 10.1177/0300060519897505.


References
1.
Malberti F, Marcelli D, Conte F, Limido A, Spotti D, Locatelli F . Parathyroidectomy in patients on renal replacement therapy: an epidemiologic study. J Am Soc Nephrol. 2001; 12(6):1242-1248. DOI: 10.1681/ASN.V1261242. View

2.
Scialla J, Wolf M . When there will never be a randomized controlled trial. Kidney Int. 2015; 88(2):220-2. PMC: 5505498. DOI: 10.1038/ki.2015.123. View

3.
Fukagawa M, Nakanishi S . Role of parathyroid intervention in the management of secondary hyperparathyroidism. Nephrol Dial Transplant. 2003; 18 Suppl 3:iii23-6. DOI: 10.1093/ndt/gfg1006. View

4.
. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003; 42(4 Suppl 3):S1-201. View

5.
Kestenbaum B, Seliger S, Gillen D, Wasse H, Young B, Sherrard D . Parathyroidectomy rates among United States dialysis patients: 1990-1999. Kidney Int. 2003; 65(1):282-8. DOI: 10.1111/j.1523-1755.2004.00368.x. View